Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

BRG1/SMARCA4 inactivation promotes non-small cell lung cancer aggressiveness by altering chromatin organization.

Orvis T, Hepperla A, Walter V, Song S, Simon J, Parker J, Wilkerson MD, Desai N, Major MB, Hayes DN, Davis IJ, Weissman B.

Cancer Res. 2014 Nov 15;74(22):6486-6498. doi: 10.1158/0008-5472.CAN-14-0061. Epub 2014 Aug 12.

2.

Gene silencing associated with SWI/SNF complex loss during NSCLC development.

Song S, Walter V, Karaca M, Li Y, Bartlett CS, Smiraglia DJ, Serber D, Sproul CD, Plass C, Zhang J, Hayes DN, Zheng Y, Weissman BE.

Mol Cancer Res. 2014 Apr;12(4):560-70. doi: 10.1158/1541-7786.MCR-13-0427. Epub 2014 Jan 20.

3.

A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1.

Oike T, Ogiwara H, Tominaga Y, Ito K, Ando O, Tsuta K, Mizukami T, Shimada Y, Isomura H, Komachi M, Furuta K, Watanabe S, Nakano T, Yokota J, Kohno T.

Cancer Res. 2013 Sep 1;73(17):5508-18. doi: 10.1158/0008-5472.CAN-12-4593. Epub 2013 Jul 19.

4.

Frequent BRG1/SMARCA4-inactivating mutations in human lung cancer cell lines.

Medina PP, Romero OA, Kohno T, Montuenga LM, Pio R, Yokota J, Sanchez-Cespedes M.

Hum Mutat. 2008 May;29(5):617-22. doi: 10.1002/humu.20730.

PMID:
18386774
5.

Swi/Snf chromatin remodeling/tumor suppressor complex establishes nucleosome occupancy at target promoters.

Tolstorukov MY, Sansam CG, Lu P, Koellhoffer EC, Helming KC, Alver BH, Tillman EJ, Evans JA, Wilson BG, Park PJ, Roberts CW.

Proc Natl Acad Sci U S A. 2013 Jun 18;110(25):10165-70. doi: 10.1073/pnas.1302209110. Epub 2013 May 30.

6.

Transcriptional targets of the chromatin-remodelling factor SMARCA4/BRG1 in lung cancer cells.

Medina PP, Carretero J, Ballestar E, Angulo B, Lopez-Rios F, Esteller M, Sanchez-Cespedes M.

Hum Mol Genet. 2005 Apr 1;14(7):973-82. Epub 2005 Feb 24.

PMID:
15731117
7.

Genetic and epigenetic screening for gene alterations of the chromatin-remodeling factor, SMARCA4/BRG1, in lung tumors.

Medina PP, Carretero J, Fraga MF, Esteller M, Sidransky D, Sanchez-Cespedes M.

Genes Chromosomes Cancer. 2004 Oct;41(2):170-7. Erratum in: Genes Chromosomes Cancer. 2005 Feb;42(2):211.

PMID:
15287030
8.

Cdx2 Regulates Gene Expression through Recruitment of Brg1-associated Switch-Sucrose Non-fermentable (SWI-SNF) Chromatin Remodeling Activity.

Nguyen TT, Savory JG, Brooke-Bisschop T, Ringuette R, Foley T, Hess BL, Mulatz KJ, Trinkle-Mulcahy L, Lohnes D.

J Biol Chem. 2017 Feb 24;292(8):3389-3399. doi: 10.1074/jbc.M116.752774. Epub 2017 Jan 12.

PMID:
28082674
9.

MAX inactivation in small cell lung cancer disrupts MYC-SWI/SNF programs and is synthetic lethal with BRG1.

Romero OA, Torres-Diz M, Pros E, Savola S, Gomez A, Moran S, Saez C, Iwakawa R, Villanueva A, Montuenga LM, Kohno T, Yokota J, Sanchez-Cespedes M.

Cancer Discov. 2014 Mar;4(3):292-303. doi: 10.1158/2159-8290.CD-13-0799. Epub 2013 Dec 20.

10.

BRG1 mutations found in human cancer cell lines inactivate Rb-mediated cell-cycle arrest.

Bartlett C, Orvis TJ, Rosson GS, Weissman BE.

J Cell Physiol. 2011 Aug;226(8):1989-97. doi: 10.1002/jcp.22533.

11.

Systematic In Vivo Inactivation of Chromatin-Regulating Enzymes Identifies Setd2 as a Potent Tumor Suppressor in Lung Adenocarcinoma.

Walter DM, Venancio OS, Buza EL, Tobias JW, Deshpande C, Gudiel AA, Kim-Kiselak C, Cicchini M, Yates TJ, Feldser DM.

Cancer Res. 2017 Apr 1;77(7):1719-1729. doi: 10.1158/0008-5472.CAN-16-2159. Epub 2017 Feb 15.

PMID:
28202515
12.

Downregulation of SWI/SNF chromatin remodeling factor subunits modulates cisplatin cytotoxicity.

Kothandapani A, Gopalakrishnan K, Kahali B, Reisman D, Patrick SM.

Exp Cell Res. 2012 Oct 1;318(16):1973-86. doi: 10.1016/j.yexcr.2012.06.011. Epub 2012 Jun 18.

13.

SWI/SNF chromatin-remodeling factors induce changes in DNA methylation to promote transcriptional activation.

Banine F, Bartlett C, Gunawardena R, Muchardt C, Yaniv M, Knudsen ES, Weissman BE, Sherman LS.

Cancer Res. 2005 May 1;65(9):3542-7.

14.

Involvement of the chromatin-remodeling factor BRG1/SMARCA4 in human cancer.

Medina PP, Sanchez-Cespedes M.

Epigenetics. 2008 Mar-Apr;3(2):64-8. Epub 2008 Apr 17. Review. Erratum in: Epigenetics. 2008 Jul-Aug;3(4):234. Cespedes, Montse Sanchez [corrected to Sanchez-Cespedes, Montse].

PMID:
18437052
15.

SMARCA4 and SMARCA2 deficiency in non-small cell lung cancer: immunohistochemical survey of 316 consecutive specimens.

Herpel E, Rieker RJ, Dienemann H, Muley T, Meister M, Hartmann A, Warth A, Agaimy A.

Ann Diagn Pathol. 2017 Feb;26:47-51. doi: 10.1016/j.anndiagpath.2016.10.006. Epub 2016 Oct 20.

PMID:
28038711
16.
17.

The reversible epigenetic silencing of BRM: implications for clinical targeted therapy.

Glaros S, Cirrincione GM, Muchardt C, Kleer CG, Michael CW, Reisman D.

Oncogene. 2007 Oct 25;26(49):7058-66. Epub 2007 Jun 4.

PMID:
17546055
18.
19.

Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type.

Karnezis AN, Wang Y, Ramos P, Hendricks WP, Oliva E, D'Angelo E, Prat J, Nucci MR, Nielsen TO, Chow C, Leung S, Kommoss F, Kommoss S, Silva A, Ronnett BM, Rabban JT, Bowtell DD, Weissman BE, Trent JM, Gilks CB, Huntsman DG.

J Pathol. 2016 Feb;238(3):389-400. doi: 10.1002/path.4633. Epub 2015 Dec 21.

20.

Supplemental Content

Support Center